McMurray R W, Allen S H, Braun A L, Rodriguez F, Walker S E
Division of Immunology and Rheumatology, University of Missouri-Columbia 65212.
J Rheumatol. 1994 May;21(5):843-50.
To describe 4 women in whom hyperprolactinemia was associated with the development of systemic lupus erythematosus (SLE).
Clinical assessment and followup (2 cases). Chart review and interviews with the attending rheumatologist (2 cases). Detailed review and reassessment of multiple imaging studies of the pituitary.
One patient had idiopathic hyperprolactinemia, and 3 had pituitary microadenomas. Serum 17 beta-estradiol concentrations were normal in all women, but serum testosterone was suppressed in 2. SLE flares occurred in 2 individuals, one and 6 months after bromocriptine therapy was discontinued, and reinstitution of bromocriptine therapy in a patient who refused corticosteroids resulted in resolution of her SLE disease activity.
Hyperprolactinemia, which has the potential to exacerbate autoimmunity, may coexist with SLE. In these instances, bromocriptine may afford therapeutic benefit.
描述4例高催乳素血症与系统性红斑狼疮（SLE）发生相关的女性患者。
临床评估及随访（2例）。查阅病历并与主治风湿病学家访谈（2例）。对垂体的多项影像学研究进行详细回顾和重新评估。
1例患者为特发性高催乳素血症，3例有垂体微腺瘤。所有女性的血清17β-雌二醇浓度均正常，但2例患者的血清睾酮水平受到抑制。2例患者出现SLE病情活动，分别在停用溴隐亭治疗后1个月和6个月，而1例拒绝使用皮质类固醇的患者重新使用溴隐亭治疗后，SLE疾病活动得到缓解。
具有加重自身免疫潜力的高催乳素血症可能与SLE共存。在这些情况下，溴隐亭可能具有治疗益处。
